Report of Foreign Issuer (6-k)
01 December 2014 - 10:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of December, 2014
Commission File Number: 000-51310
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
85 Medinat Hayehudim St., Herzliya
Pituach, PO Box 4033,
____________Herzliya 4614001, Israel____________
(Address of principal
executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated December 1, 2014 is hereby incorporated by reference into the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.
Herzliya, 1 December 2014, XTL Biopharmaceuticals
Ltd. announces the amendment of item 3 on the agenda of the Annual General Meeting of shareholders scheduled for December 30, 2014,
so that Mr. David Bassa will not be granted any compensation, including the allotment of 150,000 non-tradable stock options.
In addition, due to the amendment above,
assuming that the full amount of the Directors Options is exercised, the shares deriving from said exercise will constitute 0.25%
of the issued and paid up capital, and 0.24% on a fully diluted basis, and assuming that the full amount of Options is exercised,
the shares deriving from said exercise will constitute 0.32% of the issued and paid up capital, and 0.31% on a fully diluted basis.
.
Other than the above-said, no additional
change is made to any other item on the agenda for the Annual General Meeting
About XTL Biopharmaceuticals Ltd. (“XTL”)
XTL Biopharmaceuticals Ltd., a biopharmaceutical
company, focuses on the acquisition and development of pharmaceutical products for the treatment of unmet clinical needs. XTL is
focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia and lupus.
XTL is a public company traded on the Nasdaq
Capital Market (NASDAQ: XTLB) and the Tel-Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv
Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
Contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080, Email: ir@xtlbio.com,
www.xtlbio.com
Cautionary Statement
Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD. |
|
|
|
|
|
|
|
|
|
|
Date: December 1, 2014 |
By: _/s/ David Kestenbaum |
|
|
David Kestenbaum |
|
|
Chief Financial Officer |
|
|
|
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024